Blood test may guide safer chemo for hodgkin lymphoma patients
NCT ID NCT06745076
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a blood test that measures tumor DNA (ctDNA) can help doctors safely reduce the amount of chemotherapy for people with advanced Hodgkin lymphoma. After two cycles of standard chemo, patients with undetectable ctDNA may receive fewer total cycles, while those with detectable ctDNA continue standard treatment. The goal is to maintain effectiveness while minimizing side effects from chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab, doxorubicin, vinblastine, dacarbazine
What this could lead to
If successful, this approach could allow many patients with advanced Hodgkin lymphoma to receive fewer chemotherapy cycles without compromising cancer control, reducing side effects.
What could go wrong
This is a phase 2 trial with only 125 participants, so results are preliminary. The ctDNA-guided reduction may not work for everyone, and some patients might still need full chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSIC HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope
NOT_YET_RECRUITINGIrvine, California, 92618, United States
Contact
-
Dana-Farber Cancer Institute
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
-
Washington University in St. Louis
RECRUITINGSt Louis, Missouri, 63110, United States
Contact